BIOMAT Database Logo BIOMAT Database Logo

Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. 1988

D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Department of Behavioral Medicine and Psychiatry, University of Virginia Medical School, Charlottesville 22901.

This study was designed to see whether the high vs low serum level of imipramine influenced the outcome of in vivo exposure therapy on patients with agoraphobia. Thirty-six subjects completed the Hopkins Symptom Checklist-90 one week before treatment and weekly throughout treatment. Both groups demonstrated equal improvement. It was noted that the rate of improvement differed for different symptom subscales: (1) Hostility, Paranoia and Psychotic symptom ratings improved over the first three weeks of treatment, (2) Interpersonal Sensitivity, Anxiety and Depression ratings improved throughout the first seven weeks of treatment and (3) Phobic Anxiety, Somatization and Obsessive Compulsure symptom ratings continued to improve throughout the entire 12 week course of treatment. Responsive vs nonresponsive subjects could be significantly differentiated after one week of treatment on the basis of their responses to the Psychoticism subscale.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010698 Phobic Disorders Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable. Claustrophobia,Neuroses, Phobic,Phobia, School,Phobias,Phobic Neuroses,Scolionophobia,Disorder, Phobic,Phobia,Phobic Disorder,School Phobia
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Combined pharmacological and behavioral treatment for agoraphobia.
January 1985, Behaviour research and therapy,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Combined behavioral therapy and pharmacotherapy of agoraphobia.
January 1993, Journal of psychiatric research,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Psychophysiological outcome of behavioral and pharmacological treatments of agoraphobia.
April 1985, Journal of consulting and clinical psychology,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Cognitive behavioral treatment of agoraphobia.
January 1987, Behaviour research and therapy,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
[Pharmacological treatment of behavioral symptoms in dementia patients].
January 2014, Przeglad lekarski,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Combined behavioral and pharmacological treatment of essential hypertension.
June 1985, Biofeedback and self-regulation,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings.
October 1982, Psychopharmacology bulletin,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Behavioral treatment of panic disorders and agoraphobia.
January 1994, Progress in behavior modification,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition.
January 2011, Neuropsychiatric disease and treatment,
D J Cox, and J C Ballenger, and M Laraia, and W R Hobbs, and G A Peterson, and A Hucek
Combined behavioral and pharmacological treatment of alcoholic methadone patients.
January 1988, Journal of substance abuse,
Copied contents to your clipboard!